Coming Soon
Bacterial Vaginosis (BV), also known as vaginal dysbiosis or Vaginal Dysbacteriosis, is a common vaginal infection. Learn about BV diagnosis, clinical documentation, and medical coding including ICD-10 codes and SNOMED CT terms for accurate healthcare records. Find information on BV symptoms, treatment, and prevention. This resource supports healthcare professionals in proper diagnosis and coding of Bacterial Vaginosis.
Also known as
Vaginitis and vulvovaginitis
Inflammation of the vagina and/or vulva.
Other noninflammatory disorders of female genital tract
Covers female genital disorders not classified elsewhere.
Infections with a predominantly sexual mode of transmission
Includes STIs, though BV isn't always considered one.
Follow this step-by-step guide to choose the correct ICD-10 code.
Is the diagnosis Bacterial Vaginosis?
When to use each related code
| Description |
|---|
| Bacterial imbalance in the vagina. |
| Yeast infection of the vagina. |
| Inflammation of the vagina. |
Using unspecified codes like N89.8 (Other specified noninflammatory disorders of vagina) when a more specific code for Bacterial Vaginosis (N76.0) is clinically supported.
Overlooking documentation suggesting BV and failing to code N76.0, impacting quality metrics and reimbursement.
Variability in coding BV (N76.0) based on documentation nuances, leading to compliance issues and inaccurate data reporting.
Q: What are the most effective bacterial vaginosis treatment strategies for recurrent cases in women of reproductive age, considering antibiotic resistance and patient comfort?
A: Recurrent bacterial vaginosis (BV) poses a significant challenge due to emerging antibiotic resistance and the impact on patient quality of life. For women of reproductive age, a multifaceted approach is crucial. Initial treatment should follow recommended guidelines, typically involving metronidazole or clindamycin. However, for recurrent BV, extending the duration of treatment or utilizing alternative routes of administration, such as vaginal metronidazole gel, may be considered. Explore how intravaginal boric acid can be implemented as an adjunct or alternative therapy, particularly for those experiencing frequent recurrences. Consider implementing strategies to restore the vaginal microbiota, such as probiotics containing Lactobacillus species, after antibiotic treatment. Patient education on modifiable risk factors, like smoking cessation and avoiding douching, is essential. Learn more about current research on novel therapeutic approaches for recurrent BV, including bacteriophage therapy and immune-modulating agents.
Q: How can I differentiate bacterial vaginosis from other vaginal infections like Trichomoniasis and Vulvovaginal Candidiasis (VVC) in a clinical setting using Amsel's criteria and microscopy?
A: Distinguishing bacterial vaginosis (BV) from Trichomoniasis and Vulvovaginal Candidiasis (VVC) requires a combination of clinical presentation and laboratory evaluation. Amsel's criteria are a valuable tool for diagnosing BV in a clinical setting. These criteria include the presence of homogenous, thin, milky discharge; vaginal pH greater than 4.5; a positive whiff test upon addition of 10% potassium hydroxide to vaginal secretions; and the presence of clue cells on microscopy. While clue cells are highly indicative of BV, microscopy also aids in differentiating other infections. Trichomoniasis typically presents with motile trichomonads observed under a microscope, often accompanied by a frothy, yellow-green discharge and vulvar irritation. In contrast, VVC typically presents with thick, white, cottage cheese-like discharge, and microscopy reveals budding yeast and pseudohyphae. Consider implementing a Nugent score analysis for a more quantitative assessment of BV based on the relative proportions of bacterial morphotypes observed under Gram stain microscopy. Explore how molecular diagnostic methods, such as PCR, can provide increased sensitivity and specificity for identifying BV and other vaginal infections.
Patient presents with complaints consistent with bacterial vaginosis (BV). She reports a thin, homogenous, off-white or gray vaginal discharge with a characteristic fishy odor, which she notes is more prominent after intercourse. The patient denies vaginal itching or burning. On speculum examination, a homogenous, milky discharge is noted in the vaginal vault. No erythema or edema of the vaginal walls or cervix is observed. A vaginal pH of >4.5 was measured using a nitrazine test. Microscopic examination of a saline wet mount revealed clue cells, indicative of BV. No trichomonads or yeast were observed. The Amsel criteria were met with positive findings for homogenous vaginal discharge, vaginal pH >4.5, positive whiff test (amine odor upon addition of 10% KOH), and the presence of clue cells on microscopy. Diagnosis of bacterial vaginosis confirmed. Treatment plan includes metronidazole 500mg orally twice daily for seven days. Patient education provided regarding medication administration, potential side effects, and avoidance of alcohol during treatment. Follow-up appointment scheduled in two weeks to assess treatment response and rule out any recurrent bacterial vaginosis. Differential diagnoses considered included trichomoniasis and vulvovaginal candidiasis, which were ruled out based on clinical findings and microscopy. ICD-10 code N89.5 assigned.